Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Book a Consultation Projections are based on the ATTAIN-MAINTAIN Phase 3 clinical trial (Eli Lilly, December 2025), which measured the average percentage of lost weight regained when patients switched from injectable GLP-1 medications to Foundayo over 52 weeks
Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function
In rodents, intracerebroventricular (ICV) administration of the GLP-1R antagonist exendin-9 suppressed the effects of peripheral GLP-1R agonist administration (liraglutide and exenatide) on food intake reduction
Is there evidence linking IGF-1 signaling to cancer risk
Neither consistently sustains long-term weight loss without medical intervention
This matters in PCOS because mitochondrial dysfunction contributes to insulin resistance, lipid accumulation, and metabolic stress
US$ 26.24
US$ 21.52
US$ 28.65
US$ 21.17
US$ 26.90
